Key Development Sanofi has upgraded its 2026 sales outlook to approximately 10% growth at constant exchange rates, above its previous... Read more
Category: Uncategorized
HEALTHCARE TRIANGLE’S EQUITY-FUNDED ACQUISITIONS REFLECT THE NEXT PHASE OF DIGITAL HEALTH CONSOLIDATION
Key Development Healthcare Triangle has completed the issuance of 12,546,540 common shares to satisfy consideration for two previously approved acquisitions,... Read more
DECENTRALISED CERTIFICATION OF TRADITIONAL MEDICINE PRACTITIONERS SIGNALS A NEW GOVERNANCE MODEL FOR VIETNAM’S TRADITIONAL HEALTHCARE SECTOR
Key Development Vietnam's Ministry of Health has proposed amendments to regulations governing the certification of traditional medicine practitioners, hereditary remedies... Read more
LAM DONG FOOD POISONING INCIDENT UNDERSCORES THE NEED FOR A MORE RESILIENT NATIONAL FOOD SAFETY SURVEILLANCE SYSTEM
Key Development Following a suspected food poisoning incident affecting 84 people after consuming bread in Lam Dong Province, Vietnam's Ministry... Read more
ADVANCED CANCER SURGERY AT PROVINCIAL HOSPITALS IS RESHAPING VIETNAM’S SPECIALISED HEALTHCARE LANDSCAPE
Key Development Nghe An General Friendship Hospital's successful implementation of advanced esophageal cancer surgery represents more than a clinical achievement.... Read more
VIETNAM-U.S. FDA COOPERATION SIGNALS A NEW PHASE OF REGULATORY MODERNISATION FOR THE HEALTHCARE INDUSTRY
Key Development Vietnam's Ministry of Health and the U.S. Food and Drug Administration (FDA) have reaffirmed their commitment to expanding... Read more
CSL’S NEXT GENERATION IMMUNOGLOBULIN MANUFACTURING PLATFORM SIGNALS A NEW COMPETITIVE ERA IN PLASMA THERAPIES
Key Development CSL has announced that it will begin clinical studies to support regulatory approval of Horizon 2, its proprietary... Read more
GSK’S US$2.52 BILLION RESTRUCTURING SIGNALS THAT BIG PHARMA IS SHIFTING FROM COST CUTTING TO PIPELINE ACCELERATION
Key Development GSK reported stronger-than-expected second quarter earnings while unveiling a US$2.52 billion restructuring programme designed to generate £1.9 billion... Read more
CAGRISEMA LAWSUIT PUTS NOVO NORDISK’S CLINICAL TRANSPARENCY AND INVESTOR TRUST UNDER NEW SCRUTINY
Key Development A US federal judge has allowed part of a shareholder lawsuit against Novo Nordisk to proceed. The surviving... Read more









